Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Immune Therapeutics Inc is a specialty pharmaceutical company operating in the USA. It engages in the commercialization of patented therapies focused on the activation and re-balancing of the body's immune system. The company is involved in acquiring the patent for the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (LDN) and Methionine [Met5]-enkephalin (MENK). It focuses on to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. The company's technology platform is built on various immunotherapies, such as Low Dose Naltrexone and Methionine-Enkephalin. It markets Low Dose Naltrexone under the IRT-103 brand.
Winter Park, FL, 32792